Treatment of Patients With Anxiety Disorder (0777-022)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Generalized Anxiety Disorder

Treatments: Drug: MK0777; Drug: Comparator: placebo (unspecified)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00539578

MK0777-022

0777-022

2007_622

Details and patient eligibility

About

The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder.

Enrollment: 270 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and Female patients ages 18 to 70

Exclusion criteria

• Women who are breastfeeding or pregnant
• Positive result at prestudy on urine drug screen for illicit drugs
• History of alcohol or drug abuse

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind